Simple SummaryT1 and T2 mapping are MRI techniques that are routinely used in the evaluation of both benign and malignant lesions in different organs and tissues. Immunohistochemical analysis is the gold standard method to assess the programmed death-ligand 1 protein (PD-L1) expression status in patients diagnosed with non-small cell lung cancer (NSCLC) to guide immunotherapy. There have been no studies on the correlation between T1 and T2 mapping values and PD-L1 expression of NSCLCs nor on the correlation between T2 mapping values and histological subtypes of lung tumors. Therefore, we present our preliminary results on the evaluation of the possible association of T1 and T2 mapping values with PD-L1 TPS and of their potential in distinguishing between the different histological subtypes of NSCLCs. In the future, T1 values could offer the possibility to help in the diagnosis and pathological classification of NSCLC through a non-invasive MRI exam.AbstractWe investigated the association of T1/T2 mapping values with programmed death-ligand 1 protein (PD-L1) expression in lung cancer and their potential in distinguishing between different histological subtypes of non-small cell lung cancers (NSCLCs). Thirty-five patients diagnosed with stage III NSCLC from April 2021 to December 2022 were included. Conventional MRI sequences were acquired with a 1.5 T system. Mean T1 and T2 mapping values were computed for six manually traced ROIs on different areas of the tumor. Data were analyzed through RStudio. Correlation between T1/T2 mapping values and PD-L1 expression was studied with a Wilcoxon–Mann–Whitney test. A Kruskal–Wallis test with a post-hoc Dunn test was used to study the correlation between T1/T2 mapping values and the histological subtypes: squamocellular carcinoma (SCC), adenocarcinoma (ADK), and poorly differentiated NSCLC (PD). There was no statistically significant correlation between T1/T2 mapping values and PD-L1 expression in NSCLC. We found statistically significant differences in T1 mapping values between ADK and SCC for the periphery ROI (p-value 0.004), the core ROI (p-value 0.01), and the whole tumor ROI (p-value 0.02). No differences were found concerning the PD NSCLCs.